7.1.2 Clinical stage Deferiprone (DFP) represents a promising clinical-stage iron chelator with oral absorbability and BBB permeability, demonstrating a favorable safety profile with low systemic toxicity, which positions it as a viable strategy for countering iron dyshomeostasis and ferroptosis in AD therapeutics (229)
BCP 157 (0.01 and 10 g/kg, i.p.) decreases the duration of catalepsy and reduces tremor severity in a mouse model of Parkinson's disease induced by MPTP.Formal Name: glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-L-valine, acetate
This can lead to an uneven concentration in the vial, which compromises its reliability for consistent dosing.
The DE type (apathetic, dreary, and complex) was determined as per Smulevich et al.10 criteria
Zinc supplementation runs you the risk of copper depletion, so the presence of copper in this formula helps replace however much you may lose.37 So far, IM8 looks like it makes good on its promise to replace common supplements
